| Arena Pharmaceuticals is a biopharmaceutical company focused on delivering medicines with pharmacology and pharmacokinetics to patients globally. Co.'s clinical programs include: etrasimod (APD334), which Co. is evaluating in ulcerative colitis, and Crohn's disease, as well as a program for atopic dermatitis; olorinab (APD371), which is is being evaluated for a range of visceral pain conditions associated with gastrointestinal diseases and for treatment of abdominal pain associated with irritable bowel syndrome; APD418, which is being evaluated in a trial for acute heart failure; and Temanogrel, a compound in its cardiovascular therapeutic area. We show 18 historical shares outstanding datapoints in our coverage of ARNA's shares outstanding history.|
Understanding the changing numbers of ARNA shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ARNA versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ARNA by allowing them to research ARNA shares outstanding history
as well as any other stock in our coverage universe.